Mylan sued over migraine medicine
Page 1 of 1
Mylan sued over migraine medicine
Would be nice if they could work together to make life better for us rather for them.............hmmmmmm
__________________________________________________________________________________
Pittsburgh Business Times - by Kris B. Mamula
Date: Thursday, August 18, 2011, 9:24am EDT
l
Canonsburg-based generic drug maker Mylan Inc. has been sued by Endo Pharmaceuticals in connection with the filing of a Food and Drug Administration application to market the generic version of Frova, which is used to treat migraine headaches, Mylan announced.
Mylan believes it is the first company to file an application to market the prescription drug, giving the company 180 days of marketing exclusivity after FDA approval. Chadds Ford Pa.-based Endo filed the lawsuit in the U.S. District Court for the District of Delaware.
For the year ending June 30, Endo had total Frova sales of $68.2 million, according to IMS Health Inc. Mylan has 162 applications pending FDA approval, representing $94.4 billion in possible annual sales. Of those applications, 43 are potential first-to-file opportunities, representing $25.5 billion in possible annual brand sales for the year ending June 30, according to Danbury Conn.-IMS Health, which tracks pharmaceutical sales data and trends.
__________________________________________________________________________________
Pittsburgh Business Times - by Kris B. Mamula
Date: Thursday, August 18, 2011, 9:24am EDT
l
Canonsburg-based generic drug maker Mylan Inc. has been sued by Endo Pharmaceuticals in connection with the filing of a Food and Drug Administration application to market the generic version of Frova, which is used to treat migraine headaches, Mylan announced.
Mylan believes it is the first company to file an application to market the prescription drug, giving the company 180 days of marketing exclusivity after FDA approval. Chadds Ford Pa.-based Endo filed the lawsuit in the U.S. District Court for the District of Delaware.
For the year ending June 30, Endo had total Frova sales of $68.2 million, according to IMS Health Inc. Mylan has 162 applications pending FDA approval, representing $94.4 billion in possible annual sales. Of those applications, 43 are potential first-to-file opportunities, representing $25.5 billion in possible annual brand sales for the year ending June 30, according to Danbury Conn.-IMS Health, which tracks pharmaceutical sales data and trends.
Similar topics
» Migraine Medicine Topamax Suspected in Birth Defect Claims
» New Paper - Written by the City of London Migraine Clinic - Progress in the Pharmacotherapy of Menstrual Migraine
» Migraine organisations hope NICE review of BOTOX will end misery of chronic migraine
» Migraine Actions -Challenging Migraine October 2011 newsletter is now available online
» National Migraine Centre (formerly the City of London Migraine Clinic) gets new brand
» New Paper - Written by the City of London Migraine Clinic - Progress in the Pharmacotherapy of Menstrual Migraine
» Migraine organisations hope NICE review of BOTOX will end misery of chronic migraine
» Migraine Actions -Challenging Migraine October 2011 newsletter is now available online
» National Migraine Centre (formerly the City of London Migraine Clinic) gets new brand
Page 1 of 1
Permissions in this forum:
You cannot reply to topics in this forum
Thu Mar 30, 2017 9:04 am by Sarah
» Facebook group - now set up
Fri Feb 24, 2017 7:43 am by Tee
» cluster headache
Wed Feb 15, 2017 3:51 pm by Heregailing
» Your view on migraines and social media
Fri Feb 10, 2017 4:17 am by Tee
» Fats and Chronic Pain/Headaches
Thu May 19, 2016 10:52 pm by Sarah
» National hospital - London
Sun Jan 10, 2016 3:18 pm by pīwakawaka
» Just saying Hello
Sun Jan 10, 2016 3:12 pm by pīwakawaka
» Botox for harmeplegic migraines
Thu Sep 24, 2015 10:59 pm by Robyn17
» Hello and thank you
Mon May 25, 2015 12:55 am by ajdesq